Clinical Trials Logo

Filter by:
NCT ID: NCT06449859 Active, not recruiting - Asthma Clinical Trials

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects

Start date: June 13, 2023
Phase: Phase 1
Study type: Interventional

The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.

NCT ID: NCT06448156 Active, not recruiting - Cardiac Arrest Clinical Trials

Epidemiological Study of Out-of-hospital Cardiac Arrest in Guangzhou

Start date: January 1, 2021
Phase:
Study type: Observational

Aim This was a population-based retrospective cohort study of OHCA. This study intends to retrospectively analyze the data of pre-hospital emergency system in Guangzhou for 10 years, explore the incidence trend of OHCA in Guangzhou for 10 years; Through further analysis, we try to explore the time distribution characteristics of OHCA in order to understand the epidemiological characteristics and rules of OHCA in super large cities in southern China. Methods The pre-hospital traffic data in the main urban area of Guangzhou Emergency Medical Command Center database from 2011 to 2020 were collected. The cases diagnosed as "cardiac arrest" and "sudden death" were screened, and the cases with non-cardiac causes in the diagnosis were deleted. The crude incidence rate and age-standardized incidence rate of OHCA were calculated. Joinpoint software was used to calculate the changing nodes in the OHCA incidence trend, and the AnnualPercent Change (APC) and Average AnnualPercent Change (Average AnnualPercent Change, APC) of OHCA incidence were calculated. AAPC). The OHCA data were grouped according to the six main urban areas, and the crude incidence rate, ASIR and changing trend of the six main urban areas were calculated. The data of OHCA were grouped by age, and the crude incidence rate, ASIR and changing trend of each age group were calculated. The data information was divided into groups according to 24 hours a day, 7 days a week, and four seasons. The number of OHCA cases in different time periods was statistically described. The data were imported into SPSS 26.0 for analysis, and Mann-Kendall test was used to evaluate the statistical significance of the time trend. Time rhythm variability was tested for mean distribution using chi-square goodness of fit test.

NCT ID: NCT06446128 Active, not recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Start date: April 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

NCT ID: NCT06443905 Active, not recruiting - Thromboembolism Clinical Trials

Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients

Start date: August 1, 2023
Phase:
Study type: Observational

The purpose of this study is to explore the efficacy, safety and cost-effectiveness of Xueshuantong (lyophilized) for the prevention of venous thromboembolism (VTE) in patients at risk of bleeding.

NCT ID: NCT06442709 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by identifying those most suitable for anticoagulant therapy. Further, the combination of anticoagulant therapy and anti-IL6R therapy has shown promising results in enhancing the prognosis of NPC patients. These findings highlight the significance of targeting the liver-lung axis and utilizing personalized treatment strategies for NPC.

NCT ID: NCT06439771 Active, not recruiting - Clinical trials for Locally Advanced or Metastatic Breast Cancer

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Start date: April 23, 2024
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression

NCT ID: NCT06435728 Active, not recruiting - Prognosis Clinical Trials

Predictive Value of Combining AccuIMR and AccuFFR in Patients With STEMI

Start date: March 1, 2024
Phase:
Study type: Observational

Patients with acute myocardial infarction were enrolled retrospectively. The fractional flow reserve (AccuFFR) and microcirculatory resistance index (AccuIMR) based on coronary angiography were analyzed, and the relationship between FFR and IMR and the prognosis of patients with acute myocardial infarction was analyzed

NCT ID: NCT06432283 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Machine Learning-based Estimated Survival Model

Start date: May 1, 2024
Phase:
Study type: Observational

Malignant tumors are the leading cause of death in elderly patients, and palliative care can improve the quality of life for elderly advanced cancer patients. One of the main reasons why these patients are not included in palliative care is the lack of accurate estimation of their survival period by patients, family members, and doctors. Both doctors and patients tend to be overly optimistic about the survival period of elderly advanced cancer patients, leading to overtreatment. Therefore, assessing the risk of death for these patients and further establishing a survival period estimation model can improve the accuracy of doctors' clinical predictions of patient survival, facilitate early referral to palliative care, and promote rationalization of medical decision-making.

NCT ID: NCT06431412 Active, not recruiting - Critical Illness Clinical Trials

A Model for Drug Concentration Prediction of Vancomycin

Start date: March 1, 2024
Phase:
Study type: Observational

Objective: This study aims to use machine learning methods to establish an optimal model for predicting serum vancomycin trough concentrations in critically ill patients. Methods: This is a single-center, retrospective study. Data on serum vancomycin concentration in the Critical Care Database of Peking Union Medical College Hospital were screened and extracted to construct a prediction model using machine learning methods. The MIMIC-IV (Medical Information Mart for Intensive Care) database will be further used for external verification of the constructed model. The study has been approved by the Medical Ethics Committee of Peking Union Medical College Hospital (K24C1161).

NCT ID: NCT06429904 Active, not recruiting - Clinical trials for Locally Advanced Pancreatic Cancer

Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Start date: May 15, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer (LAPC).